Helsinn and Lyfebulb Announce Partnership for Second Annual Patient-Driven Innovation Summit in Cancer
- The award will be presented to the Patient Entrepreneur demonstrating outstanding science and potential to bring their idea to the market for cancer patients
LUGANO, SWITZERLAND, AND NEW YORK, NY, NOV 27: Helsinn, a Swiss pharmaceutical group focused on building quality cancer care, announced that for the second consecutive year it will be collaborating with Lyfebulb, a patient empowerment platform that connects patients with industry and investors to support user-driven innovation toward solutions in chronic disease. This collaboration will kick-off with an event on December 4, 2018 in New York City and will culminate with the announcement of the winner of the 2019 Lyfebulb-Helsinn Innovation Award in Monaco on March 19, 2019.
The Helsinn-Lyfebulb Innovation Summit is open to Patient Entrepreneurs building ground-breaking companies to advance the prevention, diagnosis, management or care of cancer. Entrepreneurs eligible to enter the competition include cancer patients, cancer survivors, or those having a close relative or loved one with cancer, who have established a company to address issues encountered by cancer patients.
Helsinn and Lyfebulb will launch the process with a panel discussion focused on the cancer patient experience on December 4, 2018. Panelists will come together from patient, physician, advocacy and industry groups to discuss unmet needs in the products and services that are currently available to cancer patients and survivors today, as well as opportunities to address these issues.
Applicants for the competition must have established a company with impactful solutions to better manage and improve the quality of life of cancer patients with respect, integrity, and quality. All candidates are invited to submit applications through the Lyfebulb-Helsinn Innovation Summit & Award website at lyfebulbprod.staging.wpengine.com/innovation-award/helsinn-2019 where more information regarding eligibility and key criteria is available. Submissions may be made between December 5, 2018 and January 23, 2019.
Riccardo Braglia, Helsinn Group Vice Chairman and CEO, commented: “The Helsinn Group has been working in healthcare for over 40 years, and patients and their real life experience with cancer have always driven everything we do. Patient Entrepreneurs have a unique insight into how products and solutions can improve the experience of living with cancer and we look forward to continuing to work with Lyfebulb.”
“Thanks to ground-breaking technologies that have come to market in the past decade, cancer has evolved into a chronic disease. We look forward to continuing our collaboration with Helsinn in this critical area,” said Dr Karin (Hehenberger) Denoyer, CEO and Founder of Lyfebulb. “There is more to be done for cancer and the patient experience is integral in driving forward new ideas when it comes to managing our healthcare. We are thrilled to get to know even more brilliant entrepreneurs in the field of cancer and supportive care through this Summit.”
About Helsinn International Services sarl
Helsinn International Services sarl is the Helsinn subsidiary which provides a range of advisory services and strategic activities to the Group and its specific companies. In particular, it acts as the advisory company to Helsinn Investment Fund.
About Helsinn Investment Fund S.A., SICAR
The Helsinn Investment Fund is focused on early-stage investments in areas of high unmet patient need. Backed by the Helsinn Group, and guided by Helsinn’s core values of quality, integrity and respect, Helsinn Investment Fund aims to help companies with innovative technologies to transform new ideas into commercial solutions with the potential to impact health-related quality of life of patients.
Drawing on Helsinn’s over 40 years of investment into research and development and commercial expertise, the investment fund selects companies with technologies in a range of areas including cancer therapeutics and diagnostics, cancer supportive care, metabolic and gastrointestinal disorders, and dermatology conditions.
For more information, visit www.helsinninvestmentfund.com
About the Helsinn Group
Helsinn is a privately owned pharmaceutical group with an extensive portfolio of marketed cancer care products and a robust drug development pipeline. Since 1976, Helsinn has been improving the everyday lives of patients, guided by core family values of respect, integrity and quality. The Group works across pharmaceuticals, biotechnology, medical devices and nutritional supplements and has expertise in research, development, manufacture and the commercialization of therapeutic and supportive care products for cancer, pain and inflammation and gastroenterology. In 2016, Helsinn created the Helsinn Investment Fund to support early-stage investment opportunities in areas of unmet patient need. The company is headquartered in Lugano, Switzerland, with operating subsidiaries in Switzerland, Ireland, the U.S., Monaco and China, as well as a product presence in approximately 190 countries globally.
To learn more about Helsinn Group please visit www.helsinn.com
Lyfebulb is a chronic disease focused, patient empowerment platform that connects patients, industry (manufacturers and payers) and investors to support user-driven innovation. Lyfebulb promotes a healthy, take-charge lifestyle for those affected by chronic disease. Grounded with its strong foundation in diabetes, the company has expanded disease states covered into cancer, inflammatory bowel disease and multiple sclerosis.
For more information:
Helsinn Group Media Contact:
Group Head of Communication
Tel: +41 (0) 91 985 21 21
For more information, please visit www.helsinn.com and follow us on Twitter, LinkedIn and Vimeo.
Lyfebulb Media Contact:
Karin (Hehenberger) Denoyer, MD, PhD
CEO & Founder, Lyfebulb
Phone: + 1 917-575-0210